Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis

Blood

Volumn 127, Issue 13, 2016, Pages 1666-1675

  Das, Rupali ^a   Guan, Peng ^b   Sprague, Leslee ^b,f   Verbist, Katherine ^c   Tedrick, Paige ^c   An, Qi Angel ^c   Cheng, Cheng ^c   Kurachi, Makoto ^d   Levine, Ross ^e   Wherry, E John ^d   Canna, Scott W ^b,g   Behrens, Edward M ^b   Nichols, Kim E ^c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; GLYCOPROTEIN P 15095; HEMOGLOBIN; HERMES ANTIGEN; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 27; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PERFORIN; RUXOLITINIB; STAT1 PROTEIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR E2F1; TRANSFORMING GROWTH FACTOR BETA3; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR; JANUS KINASE; PERFORIN 1, MOUSE; PYRAZOLE DERIVATIVE;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CLINICAL LABORATORY; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; CYTOKINE STORM; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; DEGRANULATION; ENZYME INHIBITION; GENE EXPRESSION; HEMOPHAGOCYTIC SYNDROME; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTOPENIA; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CHLOROCEBUS AETHIOPS; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; PATHOLOGY; VERO CELL LINE;

ANIMALS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CPG ISLANDS; DISEASE MODELS, ANIMAL; INFLAMMATION; JANUS KINASES; LYMPHOCYTE ACTIVATION; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PERFORIN; PYRAZOLES; VERO CELLS;

EID: 85017075036     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-12-684399     Document Type: Article

References (41)

1. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63:233-246.
2. Canna SW, Behrens EM. Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr Clin North Am. 2012;59(2):329-344.
3. Janka GE, Lehmberg K. Hemophagocytic syndromes - an update. Blood Rev. 2014;28(4):135-142.
4. Trottestam H, Horne A, Aricò M, et al; Histiocyte Society. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577-4584.
5. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101-109.
6. Lykens JE, Terrell CE, Zoller EE, Risma K, Jordan MB. Perforin is a critical physiologic regulator of T-cell activation. Blood. 2011;118(3):618-626.
7. Terrell CE, Jordan MB. Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells. Blood. 2013;121(26):5184-5191.
8. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3- bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226-6233.
9. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
10. Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. Growth Factors. 2012;30(2):88-106.
11. Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol. 2012;12(4):464-470.
12. Laurence A, Pesu M, Silvennoinen O, O'Shea J. JAK kinases in health and disease: an update. Open Rheumatol J. 2012;6:232-244.
13. Villarino AV, Kanno Y, Ferdinand JR, O'Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol. 2015;194(1):21-27.
14. Fleischmann R, Kremer J, Cush J, et al; ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495-507.
15. Sandborn WJ, Ghosh S, Panes J, et al; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616-624.
16. Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012;19(26):4399-4413.
17. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
18. Behrens EM, Canna SW, Slade K, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011;121(6):2264-2277.
19. Das R, Bassiri H, Guan P, et al. The adaptor molecule SAP plays essential roles during invariant NKT cell cytotoxicity and lytic synapse formation. Blood. 2013;121(17):3386-3395.
20. Kubovcakova L, Lundberg P, Grisouard J, et al. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood. 2013;121(7):1188-1199.
21. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735-743.
22. Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015;26(3):263-280.
23. Pachlopnik Schmid J, Ho CH, Chrétien F, et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med. 2009;1(2):112-124.
24. Kögl T, Müller J, Jessen B, et al. Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease. Blood. 2013;121(4):604-613.
25. van Dommelen SL, Sumaria N, Schreiber RD, Scalzo AA, Smyth MJ, Degli-Esposti MA. Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity. 2006;25(5):835-848.
26. Chiossone L, Audonnet S, Chetaille B, et al. Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein. Front Immunol. 2012;3:239.
27. Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol. 2010;37(5):967-973.
28. Yasutomi M, Okazaki S, Hata I, et al. Cytokine profiles in Mycoplasma pneumoniae infection-associated hemophagocytic lymphohistiocytosis [published online ahead or print December 11, 2014]. J Microbiol Immunol Infect. doi:10.1016/j.jmii.2014.11.015.
29. Sumegi J, Nestheide SV, Barnes MG, et al. Gene-expression signatures differ between different clinical forms of familial hemophagocytic lymphohistiocytosis. Blood. 2013;121(7):e14-e24.
30. Wada T, Muraoka M, Yokoyama T, Toma T, Kanegane H, Yachie A. Cytokine profiles in children with primary Epstein-Barr virus infection. Pediatr Blood Cancer. 2013;60(7):E46-E48.
31. Henter JI, Elinder G, Söder O, Hansson M, Andersson B, Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991;78(11):2918-2922.
32. Takada H, Nomura A, Ohga S, Hara T. Interleukin-18 in hemophagocytic lymphohistiocytosis. Leuk Lymphoma. 2001;42(1-2):21-28.
33. Mascarenhas J. Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis. Leuk Lymphoma. 2015;56(9):2493-2497.
34. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170-181.
35. Schönberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015;75(11):2187-2199.
36. HeineA, HeldSA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122(7):1192-1202.
37. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122(23):3843-3844.
38. Parampalli Yajnanarayana S, Stübig T, Cornez I, et al. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015;169(6):824-833.
39. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154-5157.
40. Ganetsky A. Ruxolitinib: a new treatment option for myelofibrosis. Pharmacotherapy. 2013;33(1):84-92.
41. Vaddi K, Sarlis NJ, Gupta V. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert Opin Pharmacother. 2012;13(16):2397-2407.